⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21573215 | 1.00 | — | — | |
| SCHEMBL25628632 | 0.84 | — | — | |
| SCHEMBL31716453 | 0.84 | — | — | |
| SCHEMBL1058030 | 0.84 | — | — | |
| SCHEMBL6627647 | 0.80 | — | — | |
| SCHEMBL1954869 | 0.80 | — | — | |
| SCHEMBL5481363 | 0.76 | — | — | |
| SCHEMBL24520168 | 0.75 | — | — | |
| SCHEMBL13009095 | 0.75 | — | — | |
| SCHEMBL1192557 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135842-B1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-23 | — | — | EP | disclosed |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| EP-4135842-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN Pharmaceutica NV (BE) | 2023-02-22 | — | — | EP | disclosed |
| CN-115485026-A | Pyrazolo [1,2-D ] [1,2,4] triazin-2-yl-acetamides as NLRP3 inflammatory pathway inhibitors | 詹森药业有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| CN-105899508-A | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140057937-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057937-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2114937-B1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-06-29 | — | — | EP | disclosed |
| US-7732440-B2 | Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20090325942-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-31 | — | — | US | disclosed |
| EP-2114937-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008089892-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-31 | — | — | WO | disclosed |